Product
Nivolumab/Relatlimab
1 clinical trial
2 indications
Indication
MelanomaIndication
melanomaClinical trial
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaStatus: Recruiting, Estimated PCD: 2025-06-01